Market Intelligence, Clinical Progress, and High-Purity Reagents for Anti-Angiogenic, Metabolic, and Infectious Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for METAP2 (Methionine Aminopeptidase 2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Catalytic Domain) | METAP2 Recombinant Protein (Full-Length & Catalytic Domain). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Co²⁺-dependent activity. | View METAP2 Products |
| Paralog Control | METAP1 Recombinant Protein. For selectivity counter-screening vs. METAP2. Sequence Verified. | View METAP1 Products |
| Substrate | Met-AMC / Met-GFP Reporter Constructs. For fluorogenic enzyme activity assays. | View METAP2 Products |
| Gene Delivery | METAP2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (overexpression/knockdown rescue). HEK293 expressed. | View METAP2 Products |
| Validator | METAP2 siRNA Set. For knockdown verification and specificity control. | View METAP2 Products |
| Benchmark Ab | Anti-METAP2 Monoclonal Antibody. Recombinant clone for ELISA, Western blot, SPR assay development, and positive control. | View METAP2 Products |
| Pathway Partner A | VEGFA Recombinant Protein. Angiogenesis pathway synergy node for co-targeting validation. | View VEGFA Products |
| Pathway Partner B | KDR / VEGFR2 Recombinant Protein. Downstream angiogenic signaling; cross-talk analysis. | View KDR Products |
| Pathway Partner C | NMT1 / NMT2 Recombinant Protein. N-myristoyltransferase; complementary target for protein N-terminal processing. | View NMT1 Products |
| Pathway Partner D | EIF2S1 (eIF2α) Recombinant Protein. Binding partner in translational regulation; PPI analysis. | View EIF2S1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (METAP1 vs METAP2) | Purified METAP1 & METAP2 ortholog proteins with >95% purity; mass spectrometry identity-confirmed for definitive selectivity profiling. |
| Cross-Species Evaluation (Human/Mouse/Cyno/Parasite) | Human, mouse, cynomolgus, and Plasmodium falciparum METAP2 recombinant proteins with matched QC standards for preclinical bridging and anti-infective screening. |
| Enzymatic Activity & Inhibitor Screening | High-purity active METAP2 (catalytic domain) for fluorescence-based activity assays; Co²⁺-loaded with defined stoichiometry. |
| Cellular Target Engagement | Matched Lentivirus ORF and siRNA for rescue experiments; validate target engagement in HUVEC tube formation assays. |
| Metal Ion Dependency Validation | Co²⁺-loaded recombinant proteins suitable for mechanistic enzymology and inhibitor binding studies. |
| False Positive Control | Validated siRNA included for specificity checks; Benchmark Antibodies for assay standardization. |
Live METAP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The METAP2 inhibitor landscape has undergone significant recalibration after the discontinuation of beloranib (Zafgen) for Prader-Willi syndrome due to thromboembolic safety signals. First-generation fumagillin analogs (TNP-470) suffered from neurotoxicity and poor PK. Despite setbacks, the biological rationale remains robust: METAP2 is essential for endothelial cell proliferation, angiogenesis, and translational control of cytoskeletal regulators.
Current R&D pivots toward:
- Isoform-selective reversible inhibitors to avoid METAP1 cross-reactivity and improve safety.
- Anti-infective applications (malaria, leishmaniasis) exploiting target divergence between human and parasite orthologs.
- PROTAC / degrader modalities for oncology to achieve deeper target elimination.
- Combination strategies with VEGFA pathway inhibitors or immune checkpoint modulators.
Future outlook (3–5 years) emphasizes safety re-engineering, tissue-specific delivery (e.g., liver targeting for metabolic disease, local ocular administration for AMD), and predictive resistance mutation profiling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Irreversible/Covalent) | Takeda (TNP-470 legacy), Academic consortia | Solid Tumors, Glioma | Covalent binding confirmation; long-term enzyme activity stability assays. |
| Small Molecule (Reversible/Allosteric) | Zafgen (beloranib – discontinued), Structure-based design groups | Obesity, Metabolic Disorders | High-throughput METAP2 vs. METAP1 selectivity panel (need purified paralogs). |
| Anti-Infective | MMV, DNDi | Malaria, Trypanosomiasis | Human vs. Parasite ortholog selectivity screening (need cross-species proteins). |
| PROTAC / Degrader | Emerging Startups | Oncology | Degradation assays (need benchmark antibodies and siRNA for target engagement). |
| Combination (Anti-angiogenic) | Clinical Investigators | Oncology | Pathway co-targeting (need METAP2 + VEGFA reagents). |
Note: METAP2 is an intracellular soluble metalloenzyme. Current therapeutic strategies focus on small molecule inhibition; biologics are limited by poor intracellular delivery.